This bispecific antibody shows remarkable increases in cell proliferation inhibitory effects, compared to the cases treated individually with the anti-c-Met antibody and the anti-EGFR antibody. ME22S induces dissociation of the Met-EGFR complex from Hsp90, followed by significant degradation of Met and EGFR. It is also capable of reducing the expression of both EGFR and Met and significantly inhibiting the cell migration, invasion, and proliferation of laryngeal cancer cells in vitro.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAND-L008 | Recombinant Anti-MET × Anti-EGFR Bispecific Antibody (Tandem Diabody) | FuncS, Promising therapeutic agent | Tandem Diabody |
CAT | Product Name | Application | Type |
---|---|---|---|
TRIAB-MZ007 | Recombinant Mouse Anti-MET × Anti-EGFR Bispecific Antibody (Triplebody) | FC | Triplebody |
There are currently no Customer reviews or questions for TRIAB-MZ006. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.